Related Experiment Videos
Droperidol: should the black box be light gray?
1Department of Anesthesiology, University of Massachusetts Medical School, Worcester, MA 01655, USA. mark.dershwitz@umassmed.edu
Journal of Clinical Anesthesia
|February 5, 2003
Summary
The FDA issued a black box warning for droperidol due to potential cardiac risks. However, a review of 19 cases suggests confounding factors make it difficult to blame droperidol for these adverse events.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- The United States Food and Drug Administration (FDA) issued a "black box" warning for droperidol in December 2001.
- The warning cited potential associations with malignant ventricular dysrhythmias, including torsade de pointes, even at doses used for postoperative nausea and vomiting.
Purpose of the Study:
- To critically review cases where droperidol doses under 10 mg were allegedly linked to ventricular dysrhythmias.
- To assess the evidence supporting droperidol as the causative agent in these reported adverse events.
Main Methods:
- Detailed review of 19 reported cases involving droperidol and ventricular dysrhythmias.
- Analysis of confounding factors present in each case to evaluate causality.
Main Results:
- The review identified significant confounding issues in the majority of the analyzed cases.
- These confounding factors complicate the direct attribution of ventricular dysrhythmias to droperidol administration.
Conclusions:
- The available evidence, considering confounding factors, makes it challenging to definitively incriminate droperidol as the cause of the reported dysrhythmias.
- Further investigation may be needed to clarify the role of droperidol in these cardiac events.